Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BB2603 for Distal Subungual Onychomycosis
NCT04188574Phase 2Completed
- Sponsor
- Blueberry Therapeutics
- Start
- Mar 2021
- Primary completion
- Dec 2022
- Modality
- Nanoparticles, Small Molecules
- Countries
- 3
01
Overview
A Phase 2 trial of BB2603 in distal subungual onychomycosis (DSO), sponsored by Blueberry Therapeutics. Started Mar 2021; status: completed.
02
Drugs
BB2603
03
Conditions
distal subungual onychomycosis (DSO)
Beyond the preview
Go deeper on NCT04188574.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04188574.